RxDoctor Payments Data

Debra Cressman, MD

Family Medicine · Walnutport, PANPI 1386790590

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 70 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$375
  • Boehringer Ingelheim$262
  • GSK$85
  • Sanofi-aventis U.S. LLC$70
  • Novo Nordisk$68
  • Pfizer$58
  • plus $163 from 5 others

What the payments were for

  • Food & beverage$1,05898%
  • Education$242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,081 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$108,050
Medicare patients
181
Services billed
1,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$47,810
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$42,979
EliquisApixaban26$23,571
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$23,259
MounjaroTirzepatide18$22,089
ArexvyRsvpref3 Antigen/As01e/Pf68$20,167
Breo ElliptaFluticasone/Vilanterol35$17,794
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,955
TrulicityDulaglutide12$12,779
ShingrixVaricella-Zoster Ge/As01b/Pf36$7,487
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$5,773
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,136
SynthroidLevothyroxine Sodium70$2,734
Novolog FlexpenInsulin Aspart14$2,358
Atorvastatin Calcium267$2,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Breo Ellipta, Trelegy Ellipta, Shingrix$85$61,403160 claims
Boehringer IngelheimJardiance$262$47,81038 claims
Lilly USA, LLCMounjaro, Trulicity$375$34,86830 claims
PfizerEliquis$58$23,57126 claims
AbbVieSynthroid$21$2,73470 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Walnutport

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →